Evidence map›Paper›PMID 31537884›Full record

ArticleScientific reports2019

The specific seroreactivity to ∆Np73 isoforms shows higher diagnostic ability in colorectal cancer patients than the canonical p73 protein.

María Garranzo-Asensio, Ana Guzmán-Aránguez, Carmen Povés, María Jesús Fernández-Aceñero, Ana Montero-Calle, María Ángeles Ceron, Servando Fernandez-Diez, Nuria Rodríguez, Marta Gómez de Cedrón, Ana Ramírez de Molina and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. The Splicing Factor PTBP1 RepressesCancer research communications · 2022
    Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

María Garranzo-AsensioDepartamento de Bioquímica y Biología Molecular, Facultad de Óptica y Optometría, Universidad Complutense de Madrid, E-28040, Madrid, Spain.
Ana Guzmán-AránguezDepartamento de Bioquímica y Biología Molecular, Facultad de Óptica y Optometría, Universidad Complutense de Madrid, E-28040, Madrid, Spain.
Carmen PovésGastroenterology Unit, Hospital Universitario Clínico San Carlos, E-28040, Madrid, Spain.
María Jesús Fernández-AceñeroSurgical Pathology Department, Hospital Universitario Clínico San Carlos, E-28040, Madrid, Spain.
Ana Montero-CalleUFIEC, Chronic Disease Programme, Instituto de Salud Carlos III, Majadahonda, E-28220, Madrid, Spain.
María Ángeles CeronSurgical Pathology Department, Hospital Universitario Clínico San Carlos, E-28040, Madrid, Spain.
Servando Fernandez-DiezGastroenterology Unit, Hospital Universitario Clínico San Carlos, E-28040, Madrid, Spain.
Nuria RodríguezMedical Oncology Department, Hospital Universitario La Paz, E-28046, Madrid, Spain.
Marta Gómez de CedrónMolecular Oncology and Nutritional Genomics of Cancer, IMDEA-FOOD, E-28049, Madrid, Spain.
Ana Ramírez de MolinaMolecular Oncology and Nutritional Genomics of Cancer, IMDEA-FOOD, E-28049, Madrid, Spain.
Gemma DomínguezDepartamento de Medicina, Facultad de Medicina, Instituto de Investigaciones Biomédicas "Alberto Sols", CSIC-UAM, E-28029, Madrid, Spain. gdominguez@iib.uam.es.
Rodrigo BarderasUFIEC, Chronic Disease Programme, Instituto de Salud Carlos III, Majadahonda, E-28220, Madrid, Spain. r.barderasm@isciii.es.ORCID http://orcid.org/0000-0003-3539-7469
Hospital Clínico San Carlos · ESInstituto de Salud Carlos III · ESMadrid Institute for Advanced Studies · ESUniversidad Complutense de Madrid · ESHospital Universitario La Paz · ESInstituto de Investigaciones Biomédicas Sols-Morreale · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The p53-family is tightly regulated at transcriptional level. Due to alternative splicing, up to 40 different theoretical proteoforms have been described for p73 and at least 20 and 10 for p53 and p63, respectively. However, only the canonical proteins have been evaluated as autoantibody targets in cancer patients for diagnosis. In this study, we have cloned and expressed in vitro the most upregulated proteoforms of p73, ΔNp73α and ΔNp73β, for the analysis of their seroreactivity by a developed luminescence based immunoassay test using 145 individual plasma from colorectal cancer, premalignant individuals and healthy controls. ∆Np73α seroreactivity showed the highest diagnostic ability to discriminate between groups. The combination of ∆Np73α, ∆Np73β and p73 proteoforms seroreactivity were able to improve their individual diagnostic ability. Competitive inhibition experiments further demonstrated the presence of unique specific epitopes in ΔNp73 isoforms not present in p73, with several colorectal patients showing unique and specific seroreactivity to the ΔNp73 proteoforms. Overall, we have increased the complexity of the humoral immune response to the p53-family in cancer patients, showing that the proteoforms derived from the alternative splicing of p73 possess a higher diagnostic ability than the canonical protein, which might be extensive for p53 and p63 proteins.

Indexed as

AdultAgedAged, 80 and overAlternative SplicingColorectal NeoplasmsDNA-Binding ProteinsFemaleGenes, p53Genes, Tumor SuppressorHumansMaleMiddle AgedNuclear ProteinsProtein IsoformsSerologic TestsTrans-Activatorsdelta Np73 protein, humanDNA-Binding ProteinsNuclear ProteinsProtein IsoformsTP73 protein, humanTrans-ActivatorsTranscription FactorsTumor Protein p73Tumor Suppressor Protein p53Tumor Suppressor Proteins

Identifiers

PMID31537884
PMCPMC6753153
OpenAlexW2974138810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.